MGF (Mechano Growth Factor)

At a glance

Standard Protocol

Alternative Titration 1

GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (IGF-1 Splice Variant); route Subcutaneous/Intramuscular; timing Post-Workout. Unapproved or source-dataset dosing tables are hypotheses, not recommendations.

• Hypoglycemia: the primary and most clinically significant risk; MGF activates IGF-1 receptors which have insulin-like glucose-lowering activity; risk is elevated with fasted administration, high doses, or stacking with IGF-1 LR3; always administer with carbohydrates and protein available.
• Localized injection site swelling: intramuscular injection causes localized inflammatory response; bilateral swelling of injected muscle groups is expected and typically resolves within 24-48 hours.
• Pain and soreness at IM injection sites.
• Excessive localized muscle swelling if dosing is imprecise: injecting too high a dose into a single small muscle (e.g., bicep) can cause disproportionate swelling.
• Fatigue: transient; associated with satellite cell mobilization and the recovery process.
• Headache: rare; associated with acute IGF-1 receptor activity.
• Nausea: rare; dose-dependent.
• Risk of inefficacy with improper administration timing: the 5-7 minute half-life means delayed post-workout injection substantially reduces efficacy; timing precision is required.
• No significant systemic side effects at standard localized doses: the short half-life limits systemic exposure when injected IM; most adverse effects are localized.

• Active cancer: IGF-1 splice variant activity may accelerate tumor proliferation via satellite cell and IGF-1 receptor pathways.
• History of hormone-sensitive malignancies: breast, prostate, colorectal; IGF-1 receptor activation promotes growth in these tumor types.
• Diabetic ketoacidosis.
• Hypoglycemia or hypoglycemia unawareness: MGF shares IGF-1 receptor activity and can lower blood glucose.
• Active inflammatory myopathy or muscle disease: satellite cell activation in inflamed muscle may worsen the condition.
• Pregnancy: safety not established.
• Breastfeeding: safety not established.
• Known hypersensitivity to MGF or excipients.
• Intramuscular injection contraindicated in subjects on anticoagulant therapy: IM injection carries bleeding risk.
• Pediatric use: safety and efficacy not established.

Synergistic / related

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://pubmed.ncbi.nlm.nih.gov/?term=MGF+%28Mechano+Growth+Factor%29